Indivior set for losses after US legal defeat
Appeal court lifts block on rival anti-opioid treatment
Anti-opioid drugmaker Indivior warned on Tuesday it could lose 80% of market share “in a matter of months” to generic versions of its Suboxone drug, after a court defeat in its long-running effort to stop generic competitors entering the market.
The company said the decision by the US Court of Appeals for the Federal Circuit had lifted a hold on the generic version produced by India’s Dr. Reddy’s Laboratories (DRL).
Indivior said it had instigated its contingency plan to cut debt and some operating expenses “while preserving a strong cash balance”, adding that it would “continue to vigorously pursue our infringement cases against DRL to protect our Suboxone...patent portfolio”.
"We are disappointed that the CAFC has denied Indivior's motion for rehearing," said chief executive Shaun Thaxter. "While we ultimately believe in the strength of our patent portfolio, we acknowledge that the company faces major disruption in the immediate future from a potential material and rapid loss of market share by our SUBOXONE® film product to generic ...competition."